Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 5 (3), 133-41

Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications

Affiliations
Review

Management of Postthrombolysis Hemorrhagic and Orolingual Angioedema Complications

Cumara B O'Carroll et al. Neurohospitalist.

Abstract

Intravenous recombinant tissue plasminogen activator was first approved for the treatment of acute ischemic stroke in the United States in 1996. Thrombolytic therapy has been proven to be effective in acute ischemic stroke treatment and shown to improve long-term functional outcomes. Its use is associated with an increased risk of symptomatic intracerebral hemorrhage as well as orolingual angioedema. Our goal is to outline the management strategies for these postthrombolysis complications.

Keywords: cerebrovascular disorders; clinical specialty; intracranial hemorrhages; neurohospitalist; stroke.

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Thrombolysis-related intracerebral hemorrhage (ICH). Intraparenchymal hemorrhage in the right temporal lobe with surrounding edema and mass effect resulting in both subfalcine and transtentorial herniation.
Figure 2.
Figure 2.
Intraparenchymal brain stem (A) and left lateral intraventricular hemorrhage (B) in a patient presenting with a right anterior cerebral artery acute ischemic stroke receiving intravenous recombinant tissue-type plasminogen activator (IV r-tPA).

Similar articles

See all similar articles

Cited by 5 PubMed Central articles

LinkOut - more resources

Feedback